Affimed N.V. (AFMD) announced the FDA has granted RMAT designation to the combination therapy of Affimeds innate cell engager acimtamig and Artiva Biotherapeutics AlloNK or AB101 for the treatment of relapsed or refractory Hodgkin Lymphoma. The designation provides Affimed enhanced access to FDA resources including the potential for accelerated approval and priority review.
The combination is being evaluated in the LuminICE-203 multicenter, multi-cohort phase 2 trial. Earlier in the year, Affimed reported promising early efficacy data from cohorts 1 and 2 of the LuminICE-203 trial.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.